Tanaka Mototsugu, Ishibashi Yoshitaka, Hamasaki Yoshifumi, Kamijo Yuka, Idei Mayumi, Kawahara Takuya, Nishi Takahiro, Takeda Michio, Nonaka Hiroshi, Nangaku Masaomi, Mise Naobumi
Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo, Japan.
Division of Nephrology, Department of Medicine, Japanese Red Cross Medical Center, Tokyo, Japan.
Kidney Int Rep. 2020 Jan 23;5(4):468-474. doi: 10.1016/j.ekir.2020.01.004. eCollection 2020 Apr.
Combination therapy with peritoneal dialysis and hemodialysis (PD+HD) is widely used for PD patients with decreased residual kidney function in Japan; however, hospitalization for this combined dialysis has not been investigated so far. We compared the risk of hospitalization for PD+HD with that for HD.
A multicenter, prospective observational study was conducted on 42 PD+HD and 42 HD patients matched for age and diabetic nephropathy. The main outcome measure was the cumulative incidence of hospitalization for any cause assessed with the Kaplan-Meier method. Hospitalization rates (the number of admissions per 100 patient-years) associated with dialysis modality were also calculated. The impact of dialysis modality on time to hospitalization was analyzed using the Cox proportional hazard model.
There was no significant difference between groups in terms of age, sex, dialysis vintage, diabetic nephropathy, and comorbidities. The cumulative incidence of hospitalization did not significantly differ between the groups (log-rank test, = 0.36). Although total hospitalization rates were 66.0 in PD+HD and 59.2 in HD, hospitalization rates for the sum of PD-related infections (a composite of catheter-related infection and peritonitis) and vascular access troubles were 21.7 in PD+HD and 7.2 in HD. On univariate Cox proportional hazard analysis, dialysis modality had no significant impact on time to hospitalization.
The risk of hospitalization was not significantly different between PD+HD and HD, although PD+HD patients had a higher risk of dialysis access-related complications than HD patients.
在日本,腹膜透析与血液透析联合治疗(PD+HD)广泛应用于残余肾功能下降的腹膜透析患者;然而,迄今为止尚未对这种联合透析的住院情况进行研究。我们比较了PD+HD患者与血液透析(HD)患者的住院风险。
对42例PD+HD患者和42例年龄及糖尿病肾病相匹配的HD患者进行了一项多中心前瞻性观察研究。主要观察指标是以Kaplan-Meier法评估的任何原因导致的住院累积发生率。还计算了与透析方式相关的住院率(每100患者年的入院次数)。使用Cox比例风险模型分析透析方式对住院时间的影响。
两组在年龄、性别、透析龄、糖尿病肾病和合并症方面无显著差异。两组的住院累积发生率无显著差异(对数秩检验,P = 0.36)。虽然PD+HD组的总住院率为66.0,HD组为59.2,但PD+HD组与腹膜透析相关感染(导管相关感染和腹膜炎的综合)及血管通路问题的住院率分别为21.7和7.2。单因素Cox比例风险分析显示,透析方式对住院时间无显著影响。
PD+HD组与HD组的住院风险无显著差异,尽管PD+HD患者发生透析通路相关并发症的风险高于HD患者。